<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843842</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-007</org_study_id>
    <nct_id>NCT01843842</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children</brief_title>
  <official_title>Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper
           respiratory tract infections in children;

        -  to assess clinical efficiency of the liquid dosage form of Ergoferon for treatment acute
           upper respiratory tract infections in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall duration of a patient's participation in the trial is 6 days
      (screening/randomization, therapy onset - day 1; study therapy period - 5 days; follow-up
      period-1 day).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients demonstrating recovery/improvement in health</measure>
    <time_frame>On day 2, 3 and 4 of observation</time_frame>
    <description>Based on the data mentioned in a patient's diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of fever</measure>
    <time_frame>Changes in body temperature on day 2, 3, 4 and 5 of observation in comparison with the baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normal body temperature (≤37.0ºС)</measure>
    <time_frame>On day 2, 3, 4, 5 of observation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of clinical manifestations of acute respiratory infection (general symptoms and nasal/ throat/ chest symptoms) in scores</measure>
    <time_frame>On days 2-5 of observation</time_frame>
    <description>On day 3rd of observation based on the results of objective examination conducted by a physician; on days 2-5 - based on data mentioned in a patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of major clinical symptoms of acute respiratory infection (fever, general symptoms and nasal/ throat/ chest symptoms) in days</measure>
    <time_frame>6 days</time_frame>
    <description>Based on data mentioned in a patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of acute respiratory infection course</measure>
    <time_frame>On day 1, 2, 3, 4, 5, 6 of the treatment</time_frame>
    <description>Based on the data on area under curve for total index of severity of general symptoms and nasal/ throat/ chest symptoms on day 1, 3, 6 of observation - based on the results of objective examination conducted by a physician; on day 1, 2, 3, 4, 5 of the treatment - based on data mentioned in a patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intakes of antipyretics if indicated</measure>
    <time_frame>On day 1, 2, 3, 4 and 5 of the treatment</time_frame>
    <description>Based on data mentioned in a patient's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with exacerbation of the disease course</measure>
    <time_frame>6 days</time_frame>
    <description>The development of disease complications requiring antibiotics administration or hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Acute Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Ergoferon (5 ml 3 times a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (5 ml 3 times a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <description>Safety and Efficiency of liquid dosage form</description>
    <arm_group_label>Ergoferon (5 ml 3 times a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficiency of liquid dosage form</description>
    <arm_group_label>Placebo (5 ml 3 times a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged over 3 years and under 18 years.

          2. Patients who consulted a doctor within 24 hours after the onset of acute respiratory
             infection (body temperature no less than 38.0°C when visiting a doctor + intensity of
             symptoms ≥ 4 scores (presence of at least 1 general symptom ≥ 2 scores and 1 nasal/
             throat/ chest symptom ≥ 2 scores or greater number of symptoms with the intensity≥1
             score) during seasonal morbidity.

          3. The possibility to start therapy within 24 hours after the onset of the first symptoms
             of acute respiratory infection.

          4. Usage of contraceptive methods by sexually active teenagers of both sexes during the
             trial and within 30 days after ending of the participation in the trial.

          5. Availability of information sheet (Informed Consent form) for parents/adopters of
             patient for participation in the clinical trial, Version 2.1 or Version 2.2, signed by
             one parent/adopter of patient. For patients over 14 years - availability of
             information sheet (Informed Consent form) for participation in the clinical trial,
             Version 2.1 or Version 2.2, signed by a patient and one parent/adopter of patient.

        Exclusion Criteria:

          1. Suspected bacterial infection or presence of a severe disease requiring use of
             antibacterial drugs (including sulfanilamides).

          2. Suspected initial manifestations of diseases that have symptoms similar to acute
             respiratory infection (other infectious diseases, influenza-like syndrome at the onset
             of systemic connective tissue disorders, oncohematology and other pathology).

          3. Medical history of primary and secondary immune deficiency: a) lymphoid system
             immunodeficiency (T-cell and /or B-cell immunity chain, immunodeficiency with
             predominant antibody deficiency); b) phagocyte deficiency; c) complement factors
             deficiency; d ) combined immunodeficiency including AIDS induced by HIV infection;
             toxic, autoimmune, infectious, radial panleukopenia syndrome; general lymphocytopenia
             syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome;
             congenital asplenia; syndrome of immune complexes pathology associated with
             infectious, allergic and autoimmune diseases.

          4. Medical history of sarcoidosis.

          5. Oncological diseases.

          6. Exacebration or decompensation of chronic diseases affecting the patient's ability to
             participate in the clinical trial.

          7. Medical history of polyvalent allergy.

          8. Allergy/ intolerance to any of the components of medications used in the treatment.

          9. Impaired glucose tolerance, diabetes mellitus.

         10. Hereditary fructose intolerance (as the study drug contains maltitol).

         11. Intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot; for 1
             month prior to the inclusion in the trial.

         12. Pregnancy, unwillingness of sexually active female patients to use of contraceptive
             methods during the study.

         13. Drug addiction, alcohol usage in the amount 2 units of alcohol per day on the part of
             patient's parents/adopters.

         14. Mental disorders of patient or of patient's parents/adopters.

         15. Patient's parents/ adopters, who from investigator's point of view, will fail to
             comply with the observation requirements of the trial or with the intake regimen of
             the investigated medicines.

         16. Participation in other clinical trials in the course of 3 months prior to the
             inclusion in the trial.

         17. Patient's parent/adopter is related to the research personnel of the investigative
             site, who are directly involved in the trial or are the immediate relative of the
             researcher. The immediate relatives includes husband/wife, parents, children or
             brothers (or sisters), regardless of whether they are natural or adopted.

         18. Patient's parent/adopter works for OOO &quot;NPF &quot;Materia Medica Holding&quot; (i.e. is the
             company's employee, temporary contract worker or appointed official responsible for
             the carrying out the research) or the immediate relative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Municipal Institution &quot;Child Health City Hospital №11&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Moscow State Medical Academy named after I.M. Sechenov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education Novosibirsk State Medical University of Ministry of Health of Russian Federation</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;City Child Health Clinical Polyclinic №5&quot;</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peterburg State Health Care Institution &quot;Child Health City Hospital №45 of the Nevsky Region&quot;</name>
      <address>
        <city>St. Peterburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Health Care Institution &quot;Сity Child Health Polyclinic №44&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic №44&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192212</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;St. Petersburg State Pediatric Medical Academy&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Child Health City Hospital №22&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196650</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Alliance Biomedical-Russian group&quot;</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot; Yaroslavl State Medical Academy&quot; of Ministry of Health</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 10, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>May 24, 2017</submitted>
    <returned>October 18, 2017</returned>
    <submitted>October 30, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

